Altimmune (ALT) AI Stock Analysis

• Market Cap: $319.49M
• Dividend Yield: N/A
• Average Volume (3M): 3.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: -95.11%
• EPS Growth: 27.25%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 88,257,256
• 10 Day Avg. Volume: 3,302,253
• 30 Day Avg. Volume: 3,321,087
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 7.40K
• Enterprise Value/Gross Profit: -14.80K
• Enterprise Value/Ebitda: -1.66
• 1Y Price Target: $20.63
• Price Target Upside: 482.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 51 Neutral
• Price Target: $3.50 ▼(-1.13% Downside)

Altimmune's overall stock score reflects a mix of financial challenges and promising clinical developments. The most significant factor is the company's weak financial performance, marked by persistent losses and negative cash flows. However, the positive earnings call and corporate events highlight potential breakthroughs in clinical trials, offering a more optimistic outlook for future growth. Technical analysis and valuation remain concerns, with bearish trends and unattractive valuation metrics.

Positive Factors

Drug Development

Analyst reiterates a Buy rating for Altimmune as pemvidutide advances toward Phase 3 in MASH, with pivotal catalysts poised to de-risk the path forward.

Leadership

The appointment of Jerry Durso as Chair, former CEO of Intercept Pharmaceuticals, aligns with Altimmune's transition into late-stage development.

Negative Factors

Financial Challenges

The balance sheet hinders pemvidutide development.

Market Competition

Pemvidutide lacks clear differentiation in the increasingly competitive MASH market.

Altimmune Business Overview & Revenue Model

Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Altimmune generates revenue primarily through the development of its therapeutic candidates, which may include milestone payments from partnerships with larger pharmaceutical companies. The company has engaged in collaborations and licensing agreements that provide upfront payments, research funding, and royalties on sales of products developed through these partnerships. Additionally, Altimmune may receive funding through government grants or contracts aimed at supporting the development of its vaccines and therapies, particularly those related to infectious diseases. As the company progresses its drug candidates through clinical trials and toward commercialization, potential revenue from product sales could become a significant source of income.

Altimmune Financial Statement Overview

Summary

Altimmune's financial performance reflects significant challenges typical of early-stage biotech firms. The income statement shows net losses and declining revenues, while the cash flow statement indicates substantial cash burn. Despite a strong equity position and low leverage, the firm relies heavily on external financing.

Income Statement

Altimmune's income statement reveals consistent net losses, with a worsening net profit margin over the TTM. Revenue has sharply declined from previous years, indicating significant challenges in revenue generation. The gross profit margin is negative, reflecting higher costs than revenues, a common issue in early-stage biotech firms focusing on R&D. The EBIT and EBITDA margins are deeply negative, highlighting limited operational efficiency and profitability.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, indicating prudent financial management and low leverage risk. The equity ratio is high, supported by substantial stockholders' equity relative to total assets, suggesting financial stability. However, the recurring net losses impact the return on equity, which remains negative, reflecting challenges in generating shareholder value.

Cash Flow

Altimmune's cash flow statement underscores significant cash burn from operations, characteristic of R&D-intensive biotech companies. The operating cash flow and free cash flow are both negative, indicating the firm relies on external financing, which is partially mitigated by positive trends in financing cash flow. The company shows no significant free cash flow growth, posing a risk to long-term sustainability without continued external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.00K	20.00K	426.00K	-68.00K	4.41M	8.19M
Gross Profit	-10.00K	20.00K	-51.00K	-568.00K	-69.43M	-25.32M
EBITDA	-89.10M	-94.81M	-87.94M	-84.40M	-96.53M	-54.15M
Net Income	-87.75M	-95.06M	-88.45M	-84.71M	-97.09M	-49.04M
Balance Sheet
Total Assets	190.35M	139.31M	210.64M	206.93M	218.86M	245.12M
Cash, Cash Equivalents and Short-Term Investments	183.10M	131.89M	197.81M	184.88M	190.30M	215.92M
Total Debt	15.85M	1.68M	671.00K	1.12M	1.53M	1.82M
Total Liabilities	28.98M	15.80M	16.54M	21.64M	19.73M	19.24M
Stockholders Equity	161.37M	123.51M	194.10M	185.29M	199.13M	225.88M
Cash Flow
Free Cash Flow	-81.58M	-79.85M	-75.86M	-62.71M	-90.55M	-34.65M
Operating Cash Flow	-81.57M	-79.85M	-75.81M	-62.59M	-78.24M	-34.44M
Investing Cash Flow	110.84M	-28.39M	13.73M	-73.40M	87.52M	-72.09M
Financing Cash Flow	96.71M	10.04M	86.11M	56.78M	65.10M	213.49M

Altimmune Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALT, the sentiment is Negative. The current price of 3.54 is below the 20-day moving average (MA) of 3.63, below the 50-day MA of 4.49, and below the 200-day MA of 5.98, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 39.37 is Neutral, neither overbought nor oversold. The STOCH value of 31.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALT.

Altimmune Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	68 Neutral	$1.08B	23.15	18.17%	―	1218.82%	―
Sector *	60 Neutral	HK$19.22B	4.48	-1.43%	3.30%	11.19%	-15.58%
IVA	55 Neutral	$634.52M	―	344.74%	―	-47.32%	-26.67%
ALT	51 Neutral	$319.49M	―	-55.91%	―	-95.11%	27.25%
ORIC	43 Neutral	$941.12M	―	-43.82%	―	―	-7.33%
AUTL	41 Neutral	$465.75M	―	-52.18%	―	187.52%	26.32%
SANA	33 Underperform	$856.10M	―	-109.12%	―	―	7.58%

Altimmune Corporate Events

Altimmune Announces Positive Phase 2b Trial Results

On June 26, 2025, Altimmune announced positive topline results from its IMPACT Phase 2b trial of pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The trial showed significant MASH resolution and weight loss in participants treated with pemvidutide compared to placebo, with low discontinuation rates due to adverse events. These results suggest pemvidutide’s potential as a transformative therapy for MASH, a condition with limited current treatment options, and support further progression to Phase 3 trials.